| アブストラクト | Although the number of patients with hip fracture increased till FY2017, it remained stable over the next 3 years, possibly owing to enhanced treatment rates and changed medications. However, the number of patients with hip fracture again increased FY2021 onwards, coinciding with the COVID-19 pandemic. PURPOSE: To clarify the trends in hip fracture incidence and its relationship with pre-fracture pharmacotherapy over time in Japan. METHODS: Using Japan's National Database of Health Insurance Claims and Specific Health Checkups, we examined the number of patients with hip fracture and their osteoporosis medication status from fiscal year (FY) 2012 to FY2023. RESULTS: A total of 1,636,198 females and 460,898 males had hip fractures. The crude number of patients in FY2020 was 181,443, indicating a decrease of 654 from the previous year. The number of patients per 10,000 females decreased in FY2018 and FY2020 compared with the previous year. The osteoporosis medication rate in the year before the fracture was 33.5%-34.3% for females from FY2013 to FY2019, but it was significantly decreased to 32.4%-32.9% from FY2020 to FY2023 (p < 0.01). The pre-fracture medication rate was significantly related to the number of patients per 10,000 population (p < 0.05). Bisphosphonates were the most common drug administered after 2015. Denosumab, romosozumab, and eldecalcitol tended to increase over time. CONCLUSION: Although the number of patients with hip fractures increased until FY2017, it remained stagnant over the next 3 years, possibly due to enhanced treatment rates and changed medications. However, the number of patients with hip fractures again increased from FY2021 onwards, coinciding with the coronavirus disease 2019 (COVID-19) pandemic in Japan. Post-COVID-19, increasing adherence to effective osteoporosis medications may curb or even reduce the number of patients with hip fractures. |
|---|
| 投稿者 | Nakatoh, Shinichi; Fujimori, Kenji; Ishii, Shigeyuki; Tamaki, Junko; Okimoto, Nobukazu; Ogawa, Sumito; Iki, Masayuki |
|---|
| 組織名 | Department of Orthopedic Surgery, Asahi General Hospital, 477 Tomari, Asahimachi,;Toyama, 939-0741, Japan. nakato38@cosmo21.net.;National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Department;of Public Health, Faculty of Medicine, Kindai University, Osaka-Sayama City,;Osaka, Japan. nakato38@cosmo21.net.;Department of Health Administration and Policy, Tohoku University School of;Medicine, Sendai, Miyagi, Japan.;Osaka, Japan.;Department of Regulatory Science, School of Pharmacy, Tokyo University of;Pharmacy and Life Sciences, Hachiouji, Tokyo, Japan.;Department of Hygiene & Public Health, Osaka Medical and Pharmaceutical;University, Takatsuki, Osaka, Japan.;Okimoto Clinic, Kure-City, Hiroshima, Japan.;Department of Geriatric Medicine, Graduate School of Medicine, The University of;Tokyo, Tokyo, Japan.;Department of Public Health, Faculty of Medicine, Kindai University,;Osaka-Sayama, Osaka, Japan. |
|---|
